This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

aaiPharma Loses a Fan

In another illustration of the fading fortunes of aaiPharma (AAII), a onetime Wall Street fan has dropped his coverage of the company.

Adam Greene of First Albany Capital, told clients Tuesday he was no longer tracking the Wilmington, N.C. drug company "given the inability to make any reliable forecasts." He said that aaiPharma's announcement Monday that it was investigating "unusual sales" of two products last year "raises questions about the company's future direction."

The company yesterday also withdrew its revenue and sales guidance for the first quarter and for all of 2004, adding that it might have to re-state financial results for 2003, depending on the outcome of an investigation by outside directors and an independent law firm.

The announcement crushed aaiPharma's stock, which fell 36% to $9.77 on Monday, well below its recent 52-week high of $31.85. Shares gained 10 cents, or 1%, to $9.87.

Analysts drop coverage of companies all the time for many reasons, but Greene's decision is notable because he had been one of aaiPharma's biggest backers. He started following aaiPharma last May with a strong buy rating. He cut the rating to buy in December. Four weeks ago, he dropped his rating to neutral after aaiPharma set up a $15.9 million reserve against revenue for 2003's fourth quarter to reflect a significant number of product returns. (He doesn't own shares, but his firm is a market maker in aaiPharma's stock.)

Greene's action follows a decision by Standard & Poor's Corp. late Monday to revise its opinion on aaiPharma to negative from stable. The rating agency changed its outlook after the markets had closed.

S&P also reaffirmed below-investment grade ratings on corporate credit (B-plus), senior secured debt (BB-minus) and subordinated debt (B-minus), which it said reflected "limited growth potential" as well as its "aggressive use" of debt to finance product acquisitions. (The lowest investment grade rating is BBB-minus).

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs